Your browser doesn't support javascript.
loading
Polatuzumab vedotin in previously untreated DLBCL: an Asia subpopulation analysis from the phase 3 POLARIX trial.
Song, Yuqin; Tilly, Hervé; Rai, Shinya; Zhang, Huilai; Jin, Jie; Goto, Hideki; Terui, Yasuhito; Shin, Ho-Jin; Kim, Won Seog; Cao, Junning; Feng, Jifeng; Eom, Hyeon Seok; Kim, Tae Min; Tsai, Xavier Cheng-Hong; Gau, Jyh-Pyng; Koh, Hideo; Zhang, Liling; Song, Yongping; Yang, Yu; Li, Wei; Huang, He; Ando, Kiyoshi; Sharman, Jeff P; Sehn, Laurie H; Bu, Lilian; Wang, Xin; Jiang, Yanwen; Hirata, Jamie; Lee, Calvin; Zhu, Jun; Izutsu, Koji.
Afiliação
  • Song Y; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing, China.
  • Tilly H; Centre Henri Becquerel and University of Rouen, Rouen, France.
  • Rai S; Kindai University Hospital, Osaka, Japan.
  • Zhang H; Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China.
  • Jin J; The First Affiliated Hospital of College of Medicine, Zhejiang University, Zhejiang, China.
  • Goto H; Department of Hematology, Hokkaido University Hospital, Sapporo, Japan.
  • Terui Y; The Cancer Institute Hospital of JFCR, Tokyo, Japan.
  • Shin HJ; Pusan National University Hospital, Busan, Republic of Korea.
  • Kim WS; Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, Republic of Korea.
  • Cao J; Fudan University Shanghai Cancer Center, Shanghai, China.
  • Feng J; Jiangsu Cancer Hospital, Nanjing, China.
  • Eom HS; Center for Hematologic Malignancy, National Cancer Center, Goyang, Republic of Korea.
  • Kim TM; Seoul National University Hospital, Seoul, Republic of Korea.
  • Tsai XC; National Taiwan University Hospital, Taipei, Taiwan.
  • Gau JP; Taipei Veterans General Hospital, Taipei, Taiwan.
  • Koh H; Department of Hematology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
  • Zhang L; Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Song Y; Department of Hematology, Cancer Hospital Affiliated to Zhengzhou University, Zhengzhou, China.
  • Yang Y; Department of Lymphoma, Head and Neck Oncology, Fujian Cancer Hospital, Fuzhou, China.
  • Li W; Department of Hematology and Oncology, The First Hospital of Jilin University, Jilin, China.
  • Huang H; Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China.
  • Ando K; Department of Hematology and Oncology, Tokai University School of Medicine, Isehara, Japan.
  • Sharman JP; Willamette Valley Cancer Institute/US Oncology, Eugene, OR.
  • Sehn LH; BC Cancer Centre for Lymphoid Cancer and The University of British Columbia, Vancouver, BC, Canada.
  • Bu L; F. Hoffmann-La Roche Ltd, Shanghai, China.
  • Wang X; F. Hoffmann-La Roche Ltd, Shanghai, China.
  • Jiang Y; Genentech, Inc, South San Francisco, CA.
  • Hirata J; Genentech, Inc, South San Francisco, CA.
  • Lee C; Genentech, Inc, South San Francisco, CA.
  • Zhu J; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing, China.
  • Izutsu K; National Cancer Center Hospital, Tokyo, Japan.
Blood ; 141(16): 1971-1981, 2023 04 20.
Article em En | MEDLINE | ID: mdl-36626583
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Linfoma Difuso de Grandes Células B Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Linfoma Difuso de Grandes Células B Idioma: En Ano de publicação: 2023 Tipo de documento: Article